JP2020516663A - 炎症によって誘起されるｄｎａ損傷の阻止及び回復 - Google Patents

炎症によって誘起されるｄｎａ損傷の阻止及び回復 Download PDF

Info

Publication number
JP2020516663A
JP2020516663A JP2019556183A JP2019556183A JP2020516663A JP 2020516663 A JP2020516663 A JP 2020516663A JP 2019556183 A JP2019556183 A JP 2019556183A JP 2019556183 A JP2019556183 A JP 2019556183A JP 2020516663 A JP2020516663 A JP 2020516663A
Authority
JP
Japan
Prior art keywords
ape1
pharmaceutically acceptable
apx3330
subject
ref
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019556183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516663A5 (https=
Inventor
マーク アール． ケリー
マーク アール． ケリー
ジル フェーレンバッハー
ジル フェーレンバッハー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of JP2020516663A publication Critical patent/JP2020516663A/ja
Publication of JP2020516663A5 publication Critical patent/JP2020516663A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019556183A 2017-04-17 2018-04-16 炎症によって誘起されるｄｎａ損傷の阻止及び回復 Pending JP2020516663A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762486033P 2017-04-17 2017-04-17
US62/486,033 2017-04-17
PCT/US2018/027786 WO2018194976A1 (en) 2017-04-17 2018-04-16 Prevention and reversal of inflammation induced dna damage

Publications (2)

Publication Number Publication Date
JP2020516663A true JP2020516663A (ja) 2020-06-11
JP2020516663A5 JP2020516663A5 (https=) 2021-04-30

Family

ID=63856081

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019556183A Pending JP2020516663A (ja) 2017-04-17 2018-04-16 炎症によって誘起されるｄｎａ損傷の阻止及び回復

Country Status (5)

Country Link
US (2) US20190117602A1 (https=)
EP (1) EP3440047A4 (https=)
JP (1) JP2020516663A (https=)
CA (1) CA3060266A1 (https=)
WO (1) WO2018194976A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018175429A1 (en) * 2017-03-20 2018-09-27 Indiana University Research And Technology Corporation Use of ape1/ref-1 inhibitors in combination therapies for treatment of cancer
CN110582480B (zh) 2017-04-21 2023-11-10 塔斯马尼亚大学 治疗化合物和方法
WO2020131511A1 (en) 2018-12-17 2020-06-25 Indiana University Research And Technology Corporation Treatment of gastrointestinal disorders and symptoms thereof
CA3267730A1 (en) 2022-09-14 2024-03-21 Opus Genetics, Inc. APX3330 SALTS AND ESTERS AND THEIR THERAPEUTIC USES
CN119097711A (zh) * 2024-09-11 2024-12-10 山东大学齐鲁医院 Ape1抑制剂在制备治疗鼻窦炎药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1067653A (ja) * 1996-06-17 1998-03-10 Eisai Co Ltd 関節疾患治療剤
JP2010540544A (ja) * 2007-09-26 2010-12-24 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション 癌および血管新生の治療のための、化学療法剤と組み合わせたベンゾキノン誘導体ｅ３３３０
US20140128398A1 (en) * 2011-06-03 2014-05-08 Indiana University Research And Technology Corporation Compounds, compositions and methods for treating oxidative dna damage disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0801949A1 (en) * 1996-04-15 1997-10-22 Eisai Co., Ltd. Hypoglycemic quinone derivative
EP0813866A3 (en) * 1996-06-17 1999-01-20 Eisai Co., Ltd. Therapeutic agent for joint diseases
US20030229004A1 (en) 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
US8710095B2 (en) * 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
EP2373292A1 (en) 2008-12-23 2011-10-12 Board of Regents of the University of Texas System Inflammation targeting particles
GB201020397D0 (en) 2010-12-02 2011-01-12 Univ Nottingham Compounds
WO2012148889A1 (en) 2011-04-28 2012-11-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of human apurinic/apyrimidinic endonuclease 1
MX357284B (es) * 2011-05-26 2018-07-04 Univ Indiana Res & Tech Corp Compuestos de quinona para tratar enfermedades mediadas por ape1.
CN107184572B (zh) 2017-03-09 2020-07-28 中山大学 一种ape1抑制剂及其在制备用于治疗肿瘤和血管异常增生性疾病药物中的应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1067653A (ja) * 1996-06-17 1998-03-10 Eisai Co Ltd 関節疾患治療剤
JP2010540544A (ja) * 2007-09-26 2010-12-24 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション 癌および血管新生の治療のための、化学療法剤と組み合わせたベンゾキノン誘導体ｅ３３３０
US20140128398A1 (en) * 2011-06-03 2014-05-08 Indiana University Research And Technology Corporation Compounds, compositions and methods for treating oxidative dna damage disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DNA REPAIR, vol. 10, JPN6022009665, 2011, pages 942 - 952, ISSN: 0004727285 *
JPN.J.CLIN.IMMUNOL., vol. 37, no. 5, JPN6022009666, 2014, pages 390 - 397, ISSN: 0004988479 *
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 359, JPN6022009667, November 2016 (2016-11-01), pages 300 - 309, ISSN: 0004988478 *

Also Published As

Publication number Publication date
US11351130B2 (en) 2022-06-07
EP3440047A4 (en) 2020-04-01
US20190117602A1 (en) 2019-04-25
US20200253904A1 (en) 2020-08-13
EP3440047A1 (en) 2019-02-13
CA3060266A1 (en) 2018-10-25
WO2018194976A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
US11351130B2 (en) Prevention and reversal of inflammation induced DNA damage
De Logu et al. Schwann cell endosome CGRP signals elicit periorbital mechanical allodynia in mice
Lee et al. The myokine meteorin‐like (metrnl) improves glucose tolerance in both skeletal muscle cells and mice by targeting AMPKα2
Kalin et al. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors
Wirkner et al. P2X3 receptor involvement in pain states
Vergnolle et al. Proteinase-activated receptor-2 and hyperalgesia: a novel pain pathway
Murphy et al. Phosphorylated RPA recruits PALB2 to stalled DNA replication forks to facilitate fork recovery
Trevisan et al. Transient receptor potential Ankyrin 1 receptor stimulation by hydrogen peroxide is critical to trigger pain during monosodium urate–induced inflammation in rodents
Wang et al. Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance
US8759097B2 (en) Inhibition of dynamin related protein 1 to promote cell death
Ge et al. Phosphodiesterase 4D acts downstream of Neuropilin to control Hedgehog signal transduction and the growth of medulloblastoma
US9597369B2 (en) Inhibitors of atypical protein kinase C and their use in treating hedgehog pathway-dependent cancers
US20150025017A1 (en) Compositions and methods for treating cancer
Chen et al. The novel ribonucleotide reductase inhibitor COH29 inhibits DNA repair in vitro
Peng et al. ASIC3 mediates itch sensation in response to coincident stimulation by acid and nonproton ligand
Campanucci et al. Expression of multiple P2X receptors by glossopharyngeal neurons projecting to rat carotid body O2-chemoreceptors: role in nitric oxide-mediated efferent inhibition
Wang et al. Discovery of coumarin-based MEK1/2 PROTAC effective in human cancer cells
Padhye et al. Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer
JP2019508491A (ja) がん治療用組み合わせ
Yang et al. HIF-1α/MMP-9 promotes spinal cord central sensitization in rats with bone cancer pain
Traver et al. Targeting NPM1 in irradiated cells inhibits NPM1 binding to RAD51, RAD51 foci formation and radiosensitizes NSCLC
Eleveld et al. MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma
Zhang et al. Disruption of DNA-PKcs-mediated cGAS retention on damaged chromatin potentiates DNA damage-inducing agent-induced anti-multiple myeloma activity
Li et al. EHMT2 promotes tumorigenesis in GNAQ/11-mutant uveal melanoma via ARHGAP29-mediated RhoA pathway
Gabra et al. Decrease in N-methyl-D-aspartic acid receptor-NR2B subunit levels by intrathecal short-hairpin RNA blocks group I metabotropic glutamate receptor-mediated hyperalgesia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230106

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230106

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230126

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230131

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230217

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241003